NCT01692366View on ClinicalTrials.gov

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Myelofibrosis
Interventions
DRUG

SAR302503

"Pharmaceutical form:Capsule~Route of administration: oral"

Trial Locations (7)

Unknown

Investigational Site Number 392010, Akita

Investigational Site Number 392002, Bunkyō City

Investigational Site Number 392006, Bunkyō City

Investigational Site Number 392004, Sendai

Investigational Site Number 392008, Shinjuku-Ku

Investigational Site Number 392009, Shinjuku-Ku

Investigational Site Number 392003, Suita-Shi

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01692366 - Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly | Biotech Hunter | Biotech Hunter